title: [Cationic liposome ceftazidime combined with nano-hydroxyapatite/beta-tricalcium phosphate for treatment of chronic osteomyelitis of rabbits].
abstract: OBJECTIVE
  To observe the effect of cationic liposomal ceftazidime (CLC) combined with nano-hydroxyapatite/beta-tricalcium phosphate (n-HA/beta-TCP) in the treatment of chronic osteomyelitis of rabbits.
  
  
  METHODS
  Thirty healthy New Zealand white rabbits (4-6 months old; weighing, 2-3 kg) were selected to prepare the chronic osteomyelitis models. After 4 weeks, the gross observation, X-ray examination, and bacteriological and histopathological examinations were done; the models were made successfully in 27 rabbits. Of 27 rabbits, 24 were randomly divided into 4 groups (n = 6): only debridement was performed in group A; ceftazidime was given (90 mg/kg), twice a day for 8 weeks after debridement in group B; ceftazidime and n-HA/beta-TC were implanted after debridement in group C; and CLC and n-HA/beta-TCP were implanted after debridement in group D. Before and after treatments, X-ray examination was done, and Norden score was recorded. At 8 weeks after treatment, the specimens were harvested for gross observation and for gross bone pathological score (GBPS) using Rissing standard; half of the specimens was used for histological observation and Smeltzer scoring, the other half for bacteriological examination and calculation of the positive rate of bacteria culture.
  
  
  RESULTS
  At 8 weeks after treatment, Norden score of group D was significantly lower than that of groups A, B, and C (P < 0.05), but no significant difference was found among groups A, B, and C (P > 0.05). At 8 weeks after treatment, sinus healed in groups C and D, but sinus was observed in groups A and B; the GBPS scores of groups C and D were significantly lower than those of groups A and B (P < 0.05). The Smeltzer scores of groups C and D were significantly lower than those of groups A and B (P < 0.05). The positive rates of bacteria culture of groups C (0) and D (0) were significantly lower than those of group A (25.0%) and group B (16.7%) (P < 0.05).
  
  
  CONCLUSIONS
  CLC combined with n-HA/beta-TCP has good effect in treating chronic osteomyelitis of rabbits, and it has better effect in treating chronic osteomyelitis of rabbits than ceftazidime with n-HA/beta-TCP.
authors.affiliation: Affiliated Orthopedic Hospital, Orthopedic Office of Research of Chinese PLA, Kunming General Hospital of Chengdu Military Command of Chinese PLA, Kunming Yunnan, 650032, P R China.
authors.forename: Yixin
authors.initials: Y
authors.lastname: Wen
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Chen
authors.forename: Tianhua
authors.initials: T
authors.lastname: Zhou
authors.forename: Minghua
authors.initials: M
authors.lastname: Huang
authors.forename: Yongqing
authors.initials: Y
authors.lastname: Xu
authors.forename: Fubing
authors.initials: F
authors.lastname: Li
authors.forename: Xinyu
authors.initials: X
authors.lastname: Fan
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: He
authors.forename: Duming
authors.initials: D
authors.lastname: Yang
authors.forename: Hua
authors.initials: H
authors.lastname: Liu
mesh_terms: D000818:Animals; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003646:Debridement; D004195:Disease Models, Animal; D005260:Female; D006882:Hydroxyapatites / Q000008:administration & dosage / Q000627:therapeutic use; D008081:Liposomes; D008297:Male; D049329:Nanostructures / Q000737:chemistry; D010019:Osteomyelitis / Q000209:etiology / Q000628:therapy*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000628:therapy; D013977:Tibia / Q000473:pathology* / Q000601:surgery; D054457:Tissue Scaffolds
chemical_list: D002130:Calcium Phosphates; D006882:Hydroxyapatites; D008081:Liposomes; C485817:beta-tricalcium phosphate; C074950:hydroxyapatite-beta tricalcium phosphate; D002442:Ceftazidime